Vandetanib demonstrates antitumor activity, with a manageable safety profile, among patients with advanced RET-rearranged non-small cell lung cancer (NSCLC), according to a study presented at the European Society for Medical Oncology (ESMO) 2016.1

RET rearrangements are identified as a rate oncogenic alteration in NSCLC; researchers therefore assessed the efficacy and tolerability of the kinase inhibitor, vandetanib, which possesses RET kinase inhibitory activity, among patients who present with this mutation.

For the multicenter, single-arm, phase 2 LURET study, researchers enrolled 19 patients with advanced RET-rearranged NSCLC who failed at least 1 prior line of chemotherapy. Half had received 3 or more prior chemotherapy regimens.

Continue Reading

Among the 17 evaluable patients, 53% (95% CI, 31-74) achieved an overall response, including 9 partial responses. The disease control rate was 90%; median progression-free survival was 4.7 months (95% CI, 2.8-8.5).

Subgroup analyses demonstrated that the overall response rates were 83%, 20%, and 67% for patients with KIF5B-RET, 6 CCDC6-RET, and unknown rearrangements, respectively; median progression-free survival was 8.3, 2.9, and 4.7 months, respectively.

RELATED: Longitudinal Changes in Depression Symptoms Linked With Survival in Lung Cancer

Researchers observed no significant differences in overall response rate or progression-free survival with respect to sex or smoking status.

The most frequently reported adverse events were hypertension, diarrhea, rash, dry skin, and corrected QT interval prolongation.                                 

Reference

  1. Horiike A, Yoh K, Seto T, et al. LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC). Poster presented at: European Society for Medical Oncology (ESMO) 2016 Congress; October 7-11, 2016; Copenhagen, Denmark.

Topics:

Conference Coverage ESMO 2016 Lung Cancer Non-Small Cell Lung Cancer